Drug
Therapy Committee
Theodore
Stern, MD, Interin Chair
Dena Alioto, RPh
Kate Barba, RN
Kathryn Beauchamp, RN, MSN
Theodore Benzer, MD
Kathryn Brush, RN
Margaret Clapp, MS, RPh
John Clark, MD
Nicole Devita, RPh
Jessica Dudley, MD
Robert Hallisey, MS, RPh
David Hooper, MD
Michael Langan, MD
Donald Lloyd-Jones, MD
Benjamin
Matthews, MD
Regina Melanson, PharmD, RPh
Kathleen McKibbin, MD
Carl Rosow, MD
Nina Tolkoff-Rubin, MD
Jerry Younger, MD
Editor
Barbara Irby, MS, RPh
Web Design
Ron Imperiali, RPh
New
Treatment for Severe Septic Shock: Promising
Benefits, Important Risks
Michael Fischer, MD, BWH
Jerry Avorn, MD, BWH
Harold J. DeMonaco, MS, MGH
Massachusetts
General Hospital Guidelines for the use of Recombinant Human Activated
Protein C (rhAPC) in Severe Sepsis
Magic
Bullets for Sepsis: A Sense of Déjà Vu?
Richard B. Dew III, R.Ph.
Director, Clinical Critical Care Research
Pulmonary & Critical Care Unit, Department of Medicine, MGH
December 2001
Have
I suddenly become more popular or have the drug companies just increased
their budgets for "informational campaigns"?
Harold J. DeMonaco, M.S., Director
of Drug Therapy Management
Fun
with statistics:
Do celecoxib (Celebrex) and rofecoxib (Vioxx) increase risk of
cardiovascular events?
Harold J. DeMonaco, M.S., Director
of Drug Therapy Management
Volume XI, Issue 9
November, 2001
Why
do we continue to write for Synthroid?
Harold J. DeMonaco, M.S., Director
of Drug Therapy Management
Volume XI, Issue 8
October, 2001
Quantifying
Sleep: From Ramsay to the BIS
Sandra Abi-Nassif, PharmD, Attending
Pharmacist
Volume XI, Issue 7
September, 2001
Baycol
(cerivastatin) Withdrawn from the U.S. Market
Richard Pasternak, MD Director of Preventive Cardiology
and Cardiac Rehabilitation Program
Volume XI, Issue 6
July/August, 2001
The
New NCEP Guidelines and Current Patterns of Statin Prescribing
Harold J. DeMonaco, M.S., Director of Drug Therapy Management
Volume XI, Issue 5
June, 2001
Esomeprazole
to Replace Omeprazole at MGH
Susan M. Ingenito, PharmD Candidate, Northeastern University
Nancy Balch, PharmD, Attending Pharmacist
Sandra Abi-Nassif, PharmD, Attending Pharmacist
Robert K. Hallisey, Jr., M.S., RPh, Clinical Coordinator
Changes to Medication Administration Policies: "The 50% Rule" Recommendations of the Drug Therapy Committee
Aristolochic
Acid, Renal Damage and Urothelial Cancer: Should the Dietary Supplement
Health and Education Act be Amended?
Harold J. DeMonaco, M.S. Director of Drug Therapy Management
Volume XI, Issue 4
May, 2001
Oral
Glycoprotein IIb/IIIa Inhibitors and Increased Mortality: Quo Vadis
Anthony J. Fatalo, MS, RPh, Senior Attending Pharmacist
Volume XI, Issue 3
April, 2001
Dr.
Allen Sandler
Volume XI, Issue 2
March, 2001
The
Use of Lipid-Lowering Drugs after MI - Yet Another Opportunity to Improve
Care
Harold J. DeMonaco, M.S. Director of Drug Therapy Management
On the Lighter Side: Alternatives to Evidence Based Medicine
Volume XI, Issue 1
February, 2001